Argen X SE ADR(ARGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 4:26 PM ET (Korea 9/11 05:26)
Full metrics table
| Index | - | P/E | 37.5 | EPS (ttm) | 26.24 | Insider Own | 0.19% | Shs Outstand | 62.6M | Perf Week | -6.76% |
| Market Cap | 61.56B | Forward P/E | 25.47 | EPS next Y | 33.76% | Insider Trans | - | Shs Float | 62.4M | Perf Month | 13.8% |
| Enterprise Value | 56.42B | PEG | 0.71 | EPS next Q | 7.61 | Inst Own | 45.55% | Short Float | 1.93% | Perf Quarter | 14.13% |
| Income | 1.71B | P/S | 11.79 | EPS this Y | 47.58% | Inst Trans | -3.75% | Short Ratio | 3.79 | Perf Half Y | 35.15% |
| Sales | 5.22B | P/B | 7.23 | EPS next 5Y | 35.69% | ROA | 19.92% | Short Interest | 1.20M | Perf YTD | 17.02% |
| Book/sh | 136.01 | P/C | 11.88 | EPS past 3/5Y | - | ROE | 23.62% | 52W High | -8.27% ($1072.75) | Perf Year | 28.99% |
| Cash/sh | 82.86 | P/FCF | 53.27 | Sales past 3/5Y | 116.43% 151.37% | ROIC | 20.27% | 52W Low | 48.68% ($661.85) | Perf 3Y | 93.06% |
| Dividend Est. | - | EV/EBITDA | 36.71 | EPS Y/Y TTM | 30.28% | Gross Margin | 89.49% | Volatility(W/M) | 2.09% 2.64% | Perf 5Y | 200.93% |
| Dividend TTM | - | EV/Sales | 10.8 | Sales Y/Y TTM | 70.57% | Oper. Margin | 28.83% | ATR (14) | 29.97 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.89 | EPS Q/Q | 104.48% | Profit Margin | 32.82% | RSI (14) | 50.21 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.12 | Sales Q/Q | 60.67% | SMA20 | -2.35% ($1007.72) | Beta | 0.44 | Target Price | $1198.28 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/23 | SMA50 | 5.73% ($930.71) | Rel Volume | 0.71 | Prev Close | $1002.31 |
| Employees | 1863 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 15.41% 6.46% | SMA200 | 16.34% ($845.83) | Avg Volume(3M) | 0.32M | Price | $984.04 |
| IPO | 2017/5/18 | Option/Short | Yes/Yes | Trades | 9750 | Volume | 226,491 | Change | -1.82% |
Company
ARGX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Argenx is a global biotech company focused on treating autoimmune diseases. Built on a llama-derived antibody platform, it develops new drugs in the FcRn inhibitor class, expanding its presence in rare autoimmune areas such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Over the past 1 year, on the higher side
8% below its 1-year high.
ARGX makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +47.6% this year.
Tap to view numbers
The price looks about right
Trading at 37.5 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +93.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 45.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TBXU 0.10%
BBH 0.05%
GDOC 0.04%
IBRN 0.04%
IBB 0.04%It ranks #3 in the industry
Based on market cap of $62B.
ARGX $62B PER 37.5
VRTX $130B PER 29.9
REGN $82B PER 19.6
MRNA $55B PER -
FAQ
What kind of company is ARGX?
ARGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARGX?
The market cap of ARGX is approximately $61.6B, ranking 272 within its sector.
What is the P/E ratio of ARGX?
ARGX has a P/E ratio of approximately 37.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ARGX?
ARGX has recorded a 52-week high of $1072.75 and a low of $661.85.
